Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MK-4250 Monotherapy in ART-Naive HIV-1
NCT03351699Phase 1Completed
- Sponsor
- Merck & Co.
- Start
- Jan 2018
- Primary completion
- Nov 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of mk-4250 in human immunodeficiency virus type 1 infection (HIV-1), sponsored by Merck & Co. Primary endpoints: Change From Baseline in Plasma HIV-1 RNA Copies Per mL at 168 hours, Percentage of Participants Experiencing >=1 Adverse Events and 1 more. Started Jan 2018; status: completed.
02
Drugs
mk-4250
03
Conditions
human immunodeficiency virus type 1 infection (HIV-1)
Beyond the preview
Go deeper on NCT03351699.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03351699.